Deciphera Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 3/4
Deciphera Pharmaceuticals CEO'su Steve Hoerter, Mar2019 tarihinde atandı, in görev süresi 5.25 yıldır. in toplam yıllık tazminatı $ 6.01M olup, şirket hissesi ve opsiyonları dahil olmak üzere 12.3% maaş ve 87.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.084% ine doğrudan sahiptir ve bu hisseler $ 1.86M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 9 yıldır.
Anahtar bilgiler
Steve Hoerter
İcra Kurulu Başkanı
US$6.0m
Toplam tazminat
| CEO maaş yüzdesi | 12.3% |
| CEO görev süresi | 5.3yrs |
| CEO sahipliği | 0.08% |
| Yönetim ortalama görev süresi | 4.3yrs |
| Yönetim Kurulu ortalama görev süresi | 9yrs |
Son yönetim güncellemeleri
Recent updates
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up
Apr 30
Diving Into Deciphera Pharmaceuticals
Apr 26We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Mar 13We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 02Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?
Sep 25Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Jul 26Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Jun 22Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S
May 08We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Apr 10We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 29Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside
Aug 29Deciphera Pharmaceuticals Q2 2022 Earnings Preview
Aug 03We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully
Jul 29Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now
Feb 11Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified
Nov 22Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Aug 26Deciphera Pharmaceuticals posts data from cancer studies at ASCO21
Jun 04Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth
May 10CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$190m |
| Dec 31 2023 | US$6m | US$738k | -US$195m |
| Sep 30 2023 | n/a | n/a | -US$194m |
| Jun 30 2023 | n/a | n/a | -US$187m |
| Mar 31 2023 | n/a | n/a | -US$182m |
| Dec 31 2022 | US$4m | US$703k | -US$179m |
| Sep 30 2022 | n/a | n/a | -US$221m |
| Jun 30 2022 | n/a | n/a | -US$258m |
| Mar 31 2022 | n/a | n/a | -US$286m |
| Dec 31 2021 | US$9m | US$676k | -US$300m |
| Sep 30 2021 | n/a | n/a | -US$274m |
| Jun 30 2021 | n/a | n/a | -US$258m |
| Mar 31 2021 | n/a | n/a | -US$255m |
| Dec 31 2020 | US$8m | US$650k | -US$266m |
| Sep 30 2020 | n/a | n/a | -US$271m |
| Jun 30 2020 | n/a | n/a | -US$263m |
| Mar 31 2020 | n/a | n/a | -US$218m |
| Dec 31 2019 | US$9m | US$435k | -US$192m |
| Sep 30 2019 | n/a | n/a | -US$157m |
| Jun 30 2019 | n/a | n/a | -US$126m |
| Mar 31 2019 | n/a | n/a | -US$126m |
| Dec 31 2018 | US$447k | n/a | -US$100m |
Tazminat ve Piyasa: Steve 'ın toplam tazminatı ($USD 6.01M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.64M ).
Tazminat ve Kazançlar: Steve şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Steve Hoerter (53 yo)
5.3yrs
Görev süresi
US$6,010,712
Tazminat
Mr. Steven L. Hoerter, also known as Steve, serves as Director at ORIC Pharmaceuticals, Inc. since August 2021. He has been President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. since Ma...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 5.3yrs | US$6.01m | 0.084% $ 1.9m | |
| Executive VP | 9.3yrs | US$2.03m | 0.049% $ 1.1m | |
| Executive VP & Chief Scientific Officer | less than a year | US$3.06m | 0% $ 0 | |
| Senior VP & Chief Commercial Officer | 5.8yrs | US$1.58m | 0.036% $ 801.7k | |
| Executive VP & Chief Medical Officer | 4.7yrs | US$2.13m | 0.084% $ 1.8m | |
| Senior VP & Chief Technical Officer | less than a year | Veri yok | Veri yok | |
| Senior Vice President of Finance & Investor Relations | no data | Veri yok | Veri yok | |
| Senior VP & General Counsel | 5.3yrs | Veri yok | Veri yok | |
| Senior VP & Chief Human Resources Officer | 2.4yrs | Veri yok | Veri yok | |
| Senior VP & Chief Development Officer | 4.3yrs | Veri yok | 0.040% $ 876.3k | |
| Senior VP & Head of International | 3.3yrs | Veri yok | Veri yok | |
| Senior Vice President of Clinical Development | 3.4yrs | Veri yok | Veri yok |
4.3yrs
Ortalama Görev Süresi
53yo
Ortalama Yaş
Deneyimli Yönetim: DCPH 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 6.1yrs | US$6.01m | 0.084% $ 1.9m | |
| Independent Director | 9.3yrs | US$388.59k | 0% $ 0 | |
| Independent Director | 7.7yrs | US$396.09k | 0% $ 0 | |
| Independent Director | 7.8yrs | US$398.55k | 0% $ 0 | |
| Independent Chairman | 4.5yrs | US$403.30k | 0% $ 0 | |
| Member of Scientific Advisory Board | 9yrs | Veri yok | Veri yok | |
| Independent Director | 16.8yrs | US$414.77k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 9yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 9yrs | Veri yok | Veri yok | |
| Independent Director | 9.3yrs | US$386.05k | 0.013% $ 281.5k | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok |
9.0yrs
Ortalama Görev Süresi
62yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: DCPH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9 yıldır).